2-year, primary prevention trial conducted in patients aged ≥18 years with asymptomatic carotid disease and moderate hypercholester-olemia. Patients were initially randomized to receive low-dose rosuvastatin (5 mg/day) or high-dose rosuvastatin (40 mg/day titrated to 80 mg/day) for 2 years; ...
Sixty-eight patients were randomly assigned in a 1:1 ratio to receive a combination of low-intensity rosuvastatin (5 mg/day) and ezetimibe (10 mg/day) or high-intensity rosuvastatin (20 mg/day). The primary endpoint was the absolute difference in the HbA1c levels at 12 we...
Specific LDL and HDL targets have been replaced with high-intensity Statin if 10 year Cardiovascular Risk >20% High intensity Statin (age <75 years with 10 year Cardiovascular Risk >20%) Rosuvastatin 20-40 mg orally daily Low intensity Statin (age >75 years, or Statin intolerant) Rosuvastatin...
rosuvastatin (5 and 10 mg/day) recipients achieved significantly (all p < 0.05) greater improvements in plasma LDL-C and total cholesterol levels than those receiving atorvastatin 10 mg/day, pravastatin 20 mg/day or simvastatin 20 mg/day, according to primary endpoint intent-to-treat analyses....
AHA/ACC considers rosuvastatin 20–40 mg daily to be a high-intensity statin and rosuvastatin 5–10 mg daily to be a moderate-intensity statin.The addition of a nonstatin drug (e.g., ezetimibe, PCSK9 inhibitor) to statin therapy may be considered in certain high-risk patients who require...
According to recent studies, each 40 mg/dl reduction in LDL cholesterol by statin therapy confers a 20% reduction in ASCVD. In other words, a relative risk reduction of 30% in ASCVD by moderate-intensity therapy and 45% by high-intensity therapy has been approximated. ...
la dose identique de 10 mg/j, la rosuvastatine est plus efficace que l'atorvastatine pour atteindre l'objectif de LDL-cholestérol1,00 g/l chez les patient... Many patients at high cardiovascular risk still fail to achieve recommended LDL-C goals. Showing evidence of a difference between ...
hemostasis and etc.The patients in research group were additionally given 10 mg oral rosuvastatin,once a day for 8 weeks.The changes of blood fat,serum SOD and MIDA levels of patients in two groups before and after medical treatment were observed and recorded,and the clinical curative effect ...
More patients on combination therapy achieved an LDL < 100 mg/dl as compared to rosuvastatin alone (94 vs 79%, P < 0.001); the goal of < 70 mg/dl in high-risk patients (80 vs 35%, P < 0.001). Both treatments increased HDL about 10%. High sensitivity CRP levels also decreased ...
High-risk men and women in a managed care population received typical starting doses of rosuvastatin (10 mg/day), atorvastatin (10 mg/day), or simvastatin (20 mg/day) for 6 weeks. Those who did not meet the LDL-C target of less than 100 mg/dL at 6 weeks had their dose titrated ...